$3.08 Million in Sales Expected for Kala Pharmaceuticals Inc (NASDAQ:KALA) This Quarter

Wall Street analysts expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report sales of $3.08 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $4.27 million. The business is scheduled to announce its next quarterly earnings results on Monday, March 9th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year sales of $7.99 million for the current fiscal year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts expect that the company will report sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last released its earnings results on Thursday, November 7th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.

A number of research firms have recently weighed in on KALA. Zacks Investment Research cut Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. Oppenheimer set a $9.00 target price on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target (down previously from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $51.00 price target on shares of Kala Pharmaceuticals in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.85.

Shares of NASDAQ KALA traded down $0.13 during trading on Friday, hitting $3.99. The company had a trading volume of 92,828 shares, compared to its average volume of 247,863. The stock has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.71. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25. Kala Pharmaceuticals has a 12 month low of $3.24 and a 12 month high of $9.25. The firm has a market capitalization of $137.83 million, a P/E ratio of -1.61 and a beta of 2.21.

Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Kala Pharmaceuticals by 148.5% during the 2nd quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock valued at $26,000 after buying an additional 2,399 shares in the last quarter. Greenwich Wealth Management LLC increased its stake in Kala Pharmaceuticals by 28.7% during the second quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after acquiring an additional 2,900 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after acquiring an additional 5,806 shares during the last quarter. Marshall Wace LLP purchased a new stake in Kala Pharmaceuticals during the first quarter valued at approximately $325,000. Finally, Charles Schwab Investment Management Inc. raised its position in Kala Pharmaceuticals by 34.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock valued at $328,000 after purchasing an additional 13,271 shares during the period. Hedge funds and other institutional investors own 64.21% of the company’s stock.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: Options Trading – What is a Straddle?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.